Calgary, Alberta — September 17, 2025 — Leads & Copy — Hemostemix Inc. CEO Thomas Smeenk will present live at the Life Science Investor Forum on Thursday, September 18, 2025, at 12:00 p.m. ET. The company offers VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb-threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida’s SB 1768.
Hemostemix has established itself as the world’s #1 autologous stem cell therapy company, backed by 11 peer-reviewed publications demonstrating safety and efficacy, 498 safe treatments completed to date, and proven efficacy in no-option patients with severe angina, ischemic and non-ischemic dilated cardiomyopathy, and related co-morbidities. Smeenk’s presentation will highlight the company’s clinical record and expanding treatment opportunities.
With the recent passage of Florida Senate Bill 1768 (SB 1768), ACP-01 can now be legally offered to no-option patients in Florida.
The Life Science Investor Forum is an interactive online event where institutional and individual investors can meet and ask questions in real time.
Event Details:
Who: Thomas Smeenk, CEO, Hemostemix Inc.
What: Live Presentation at Life Science Investor Forum
When: Thursday, September 18, 2025 – 12:00 p.m. ET
Where: https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/145232/september-18th-life-sciences-virtual-investor-forum
Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
